Baidu
map

PLoS ONE:肿瘤周围组织存在抑制三阴性乳腺癌转移物质

2012-09-25 Beyond 生物谷

近日,科学家在肿瘤周围组织中发现的一种天然物质可能抑制三阴乳腺癌转移。发表在PLOS ONE杂志上的一项临床前研究证实,有抑制肿瘤生长功效的核心蛋白聚糖能诱导三阴性乳腺癌肿瘤周围组织中一系列肿瘤抑制基因的表达,导致肿瘤转移受到抑制。 三阴乳腺癌特指雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)均阴性的乳腺癌患者。托马斯·杰斐逊大学解剖学和细胞生物学Renato V.

近日,科学家在肿瘤周围组织中发现的一种天然物质可能抑制三阴乳腺癌转移。发表在PLOS ONE杂志上的一项临床前研究证实,有抑制肿瘤生长功效的核心蛋白聚糖能诱导三阴性乳腺癌肿瘤周围组织中一系列肿瘤抑制基因的表达,导致肿瘤转移受到抑制。

三阴乳腺癌特指雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)均阴性的乳腺癌患者。托马斯·杰斐逊大学解剖学和细胞生物学Renato V. Iozzo医学博士说:这一最新研究发现最终可能有助于三阴乳腺癌的临床评估和预后判断。

Iozzo博士说:起初,我们认为核心蛋白聚糖是影响肿瘤细胞本身的,但令人惊讶的是,核心蛋白聚糖是能影响肿瘤微环境的。在这项研究中,核心蛋白聚糖能导致357个基因表达增加,但更有趣的是,研究人员发现三个肿瘤抑制基因是与三阴性乳腺癌相关联的,这些抑癌基因是Bmp2K、Zc3hav1和PEG3。

核心蛋白聚糖是蛋白聚糖(proteoglycan,PG)的一种,是一种多效性分子。在调节细胞粘附、迁徙、增殖、胶原纤维形成及调节TGF-β活性中起重要作用。研究人员还发现核心蛋白聚糖能调控p21蛋白的生成,p21蛋白能抑制肿瘤细胞生长。然而,核心蛋白聚糖背后的抗乳腺癌特性和机制仍然不甚明了。
 
在这项研究中,研究人员旨在探讨核心蛋白聚糖对三阴性乳腺癌肿瘤小鼠模型体内肿瘤细胞系的影响,以及分析肿瘤微环境基因表达情况。

小鼠给予蛋白聚糖治疗23天后,肿瘤体积体积缩小达50%。然后,研究人员利用先进的芯片技术分析了小鼠肿瘤微环境中基因表达情况,发现357个基因表达增加了,其中3个是肿瘤抑制基因。这些结果表明核心蛋白聚糖有助减少或预防肿瘤转移,改善转移性乳腺癌的治疗。

 

Decorin Protein Core Affects the Global Gene Expression Profile of the Tumor Microenvironment in a Triple-Negative Orthotopic Breast Carcinoma Xenograft Model.

Simone Buraschi, Thomas Neill, Rick T. Owens, Leonardo A. Iniguez, George Purkins, Rajanikanth Vadigepalli, Barry Evans, Liliana Schaefer, Stephen C. Peiper, Zi-Xuan Wang, Renato V. Iozzo.

Decorin, a member of the small leucine-rich proteoglycan gene family, exists and functions wholly within the tumor microenvironment to suppress tumorigenesis by directly targeting and antagonizing multiple receptor tyrosine kinases, such as the EGFR and Met. This leads to potent and sustained signal attenuation, growth arrest, and angiostasis. We thus sought to evaluate the tumoricidal benefits of systemic decorin on a triple-negative orthotopic breast carcinoma xenograft model. To this end, we employed a novel high-density mixed expression array capable of differentiating and simultaneously measuring gene signatures of both Mus musculus (stromal) and Homo sapiens (epithelial) tissue origins. We found that decorin protein core modulated the differential expression of 374 genes within the stromal compartment of the tumor xenograft. Further, our top gene ontology classes strongly suggests an unexpected and preferential role for decorin protein core to inhibit genes necessary for immunomodulatory responses while simultaneously inducing expression of those possessing cellular adhesion and tumor suppressive gene properties. Rigorous verification of the top scoring candidates led to the discovery of three genes heretofore unlinked to malignant breast cancer that were reproducibly found to be induced in several models of tumor stroma. Collectively, our data provide highly novel and unexpected stromal gene signatures as a direct function of systemic administration of decorin protein core and reveals a fundamental basis of action for decorin to modulate the tumor stroma as a biological mechanism for the ascribed anti-tumorigenic properties.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789477, encodeId=51321e89477ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jan 08 22:30:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047902, encodeId=b268204e902e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Wed Feb 13 07:30:00 CST 2013, time=2013-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458637, encodeId=5f2d145863e7e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590234, encodeId=0ce515902344e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789477, encodeId=51321e89477ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jan 08 22:30:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047902, encodeId=b268204e902e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Wed Feb 13 07:30:00 CST 2013, time=2013-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458637, encodeId=5f2d145863e7e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590234, encodeId=0ce515902344e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789477, encodeId=51321e89477ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jan 08 22:30:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047902, encodeId=b268204e902e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Wed Feb 13 07:30:00 CST 2013, time=2013-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458637, encodeId=5f2d145863e7e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590234, encodeId=0ce515902344e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=)]
    2012-09-27 xlysu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789477, encodeId=51321e89477ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jan 08 22:30:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047902, encodeId=b268204e902e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Wed Feb 13 07:30:00 CST 2013, time=2013-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458637, encodeId=5f2d145863e7e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590234, encodeId=0ce515902344e, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Thu Sep 27 07:30:00 CST 2012, time=2012-09-27, status=1, ipAttribution=)]

相关资讯

中国单抗药物将迎来发展机遇

中国单抗药物将迎来黄金时代 据了解,单克隆抗体药物可直接用于人类疾病的诊断、预防、治疗以及免疫机制的研究,为人类恶性肿瘤的免疫诊断与免疫治疗开辟了广阔前景,已成为全球发展最快的药物领域之一。业内人士预计,未来几年,随着单抗药物大品种专利纷纷到期,单抗仿制药物将面临更大的发展机遇。 单抗药物迎来发展机遇 根据国金证券发布的报告,单抗行业由于具有大市场、高成长、研发壁垒的特点,一直位于生物制药“

FDA批准tob-非格司亭治疗肿瘤患者严重中性粒细胞减少症

  2012年8月29日,美国FDA批准tob-非格司亭用于特定接受化疗的患者减少严重中性粒细胞减少症。   Tob-非格司亭拟用于血液或骨髓肿瘤(非髓性恶性肿瘤)服用化疗药物导致骨髓中性粒细胞产生严重下降的成人患者,中性粒细胞的减少可能导致感染和发热(发热性中性粒细胞减少症)。   Tob-非格司亭可刺激骨髓产生中性粒细胞增加,用法是在化疗后前24小时注射。其疗效在一项纳入348例接受抗癌药

PNAS:刘小龙研究组揭示肿瘤免疫抑制新机制

9月4日,国际学术期刊《美国科学院院刊》在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所刘小龙研究组的最新研究成果Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1,该研究揭示了转录因子AP-1在肿瘤免疫抑制中的作用及分子机制。 肿瘤在发生

Sci Transl Med:RNA纳米粒子纳米粒子缩小小鼠卵巢肿瘤

通过癌症细胞的基因组测序,科学家们发现肿瘤细胞突变,删除或复制的大部分基因。这是个数据宝库,有助寻求新的药物靶标,但要想及时测试这些基因几乎是不可能的。 为了帮助加快这一进程,麻省理工学院的研究人员已经开发出了RNA纳米粒子,该技术能有助快速筛选新的药物靶标。在他们的第一项老鼠研究中,Dana-Farber癌症研究所和Broad研究院的研究人员发现,靶向ID4的纳米粒子可以缩小卵巢肿瘤。Sang

PLOS ONE:我国青蒿素类化合物抗肿瘤机制新进展

随着我国科学家凭借对青蒿素类药物的研究获得2011年国际拉斯科临床医学大奖,青蒿素及其衍生物再度成为举世瞩目的明星分子,其中双氢青蒿素(DHA)是青蒿素的主要代谢产物和活性最强的一种衍生物。近年来,王慧研究组对青蒿素类化合物的抗肿瘤功能及机制开展了多项研究,已发现青蒿素及其衍生物对卵巢癌、肝癌的抗癌效果并探讨了其作用机制。本研究中,该组巴乾等研究人员发现,DHA能造成肿瘤细胞铁元素的缺乏、降低铁元

Cancer Res:我国雷公藤内酯醇抗肿瘤研究获进展

雷公藤内酯醇是中药雷公藤的主要生物活性成分,具有包括抗肿瘤在内的多重生物学作用。中科院上海药物研究所缪泽鸿课题组、李援朝课题组、丁健课题组与意大利博洛尼亚大学Giovanni Capranico实验室合作,在雷公藤内酯醇及其衍生物的抗肿瘤作用和机制研究中取得阶段性进展。 在阐明C14β位羟基取代的雷公藤内酯醇衍生物具有选择性体内抗肿瘤作用 (J Med Chem. 2009; 52: 5115–

Baidu
map
Baidu
map
Baidu
map